Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Asset Writedowns and Impairment (2023 - 2025)

Sangamo Therapeutics has reported Asset Writedowns and Impairment over the past 4 years, most recently at $13.2 million for Q4 2025.

  • For Q4 2025, Asset Writedowns and Impairment changed N/A year-over-year to $13.2 million; the TTM value through Dec 2025 reached $13.2 million, up 139.72%, while the annual FY2025 figure was $13.2 million, 139.72% up from the prior year.
  • Asset Writedowns and Impairment for Q4 2025 was $13.2 million at Sangamo Therapeutics, up from $1.2 million in the prior quarter.
  • Over five years, Asset Writedowns and Impairment peaked at $13.2 million in Q4 2025 and troughed at $200000.0 in Q4 2023.
  • A 3-year average of $4.6 million and a median of $4.2 million in 2023 define the central range for Asset Writedowns and Impairment.
  • On a YoY basis, Asset Writedowns and Impairment climbed as much as 3.55% in 2024 and fell as far as 3.55% in 2024.
  • Year by year, Asset Writedowns and Impairment stood at $200000.0 in 2023, then surged by 486.0% to $1.2 million in 2024, then surged by 1029.27% to $13.2 million in 2025.
  • Business Quant data shows Asset Writedowns and Impairment for SGMO at $13.2 million in Q4 2025, $1.2 million in Q2 2024, and $4.3 million in Q1 2024.